Status:
COMPLETED
Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens
Lead Sponsor:
Germans Trias i Pujol Hospital
Collaborating Sponsors:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Conditions:
Hepatitis C
HIV Infections
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This trial will assess the sustained virologic response to treatment with peginterferon alfa-2a combined with high-dose ribavirin in human immunodeficiency virus (HIV)-infected patients with hepatitis...
Detailed Description
The purpose in treating chronic HCV infection in HIV-coinfected individuals is to clear HCV-RNA antibodies and cure the infection. Studies have shown that high doses of ribavirin are associated with h...
Eligibility Criteria
Inclusion
- HIV-infected patients coinfected with HCV genotypes 1 or 4
- Persistent transaminase elevation
- Nonresponders to previous treatment with peginterferon alfa plus ribavirin at a dosage of 800-1200 mg/d.
Exclusion
- Patients who abandoned treatment with peginterferon plus ribavirin before 12 weeks
- Patients with Child-Pugh B or C cirrhosis
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00470210
Start Date
May 1 2007
End Date
June 1 2009
Last Update
December 5 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916
2
Hospital del Mar
Barcelona, Spain, 08003